Anemia of Chronic Kidney Disease Clinical Trial
Official title:
Phase Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Hepcidin Antagonist PRS-080#022-DP in Anemic Chronic Kidney Disease Patients Undergoing Hemodialysis
Anticalins® are engineered human proteins that are able to bind specific target molecules. The Anticalin PRS-080#022-DP to be investigated in this study is directed against hepcidin and is intended for the treatment of anemia of chronic disease. This Phase Ib study shall investigate the safety, pharmacokinetics and pharmacodynamics of a single administration of PRS-080#022-DP in anemic stage 5 chronic kidney disease patients undergoing hemodialysis.
This is a multi-center, randomized, double-blind, placebo-controlled, single ascending dose phase Ib study in anemic stage 5 chronic kidney disease patients requiring hemodialysis. Eligible subjects will undergo screening assessments and PRS-080#22-DP will be administered by intravenous infusion. The study will consist of 3 dose cohorts of 2 mg/kg, 4 mg/kg, and 8 mg/kg body weight with 8 subjects in each cohort. Using a standard 6+2 design, 6 subjects in each cohort will be randomized to PRS-080#022-DP and 2 subjects in each cohort will be randomized to placebo. The decision to escalate the dose will be based on an interim analysis of clinical safety and safety laboratory data. Safety and tolerability, pharmacokinetics, pharmacodynamics as well as potential immunogenicity will be investigated. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03325621 -
Phase 2a Study to Evaluate PRS-080 in Anemic Chronic Kidney Disease Patients
|
Phase 1/Phase 2 | |
| Completed |
NCT02198495 -
Comparison Study of Two Iron Compounds for Treatment of Anemia in Hemodialysis Patients
|
Phase 4 | |
| Suspended |
NCT03193073 -
Anemia Correction and Fibroblast Growth Factor 23 Levels in Chronic Kidney Disease , and Renal Transplant Patient
|
N/A | |
| Completed |
NCT02581124 -
Study to Evaluate Effect of Lapatinib on Pharmacokinetics of JTZ-951 in Subjects With End-stage Renal Disease
|
Phase 1 | |
| Completed |
NCT02268994 -
KRX-0502 (Ferric Citrate) for the Treatment of IDA in Adult Subjects With NDD-CKD
|
Phase 3 | |
| Completed |
NCT04543812 -
PBF-1681 (Ferric Citrate) for the Treatment of IDA in Patients With NDD-CKD
|
Phase 3 | |
| Recruiting |
NCT05900635 -
Effect of Adding Lactoferrin on Oral Iron on Anemia in Chronic Kidney Disease Patients
|
Phase 4 | |
| Completed |
NCT04667533 -
Desidustat in the Treatment of Chemotherapy Induced Anemia
|
Phase 1 | |
| Completed |
NCT03731741 -
Does Oral Pentoxifylline Administration Improve Hemoglobin in Hemodialysis Patients?
|
Phase 2 | |
| Completed |
NCT02787824 -
Periodic Versus Continuous IV Iron Supplementation in HD Patients
|
Phase 4 | |
| Completed |
NCT03431623 -
CKD-11101 Phase 3 SC Study
|
Phase 3 | |
| Completed |
NCT01971164 -
Safety, Tolerability, PK & PD Study of JTZ-951 in Anemic Subjects With End-stage Renal Disease
|
Phase 1 | |
| Recruiting |
NCT01532349 -
Vitamin D as a Modifier of Serum Hepcidin in Children With Chronic Kidney Disease
|
Phase 2 | |
| Completed |
NCT05698420 -
Investigation of the Effects of Medium Cut-off Dialyzers Versus High-Flux Dialyzers on Clinical and Laboratory Parameters of Prevalent Hemodialysis Patients
|
||
| Completed |
NCT03427801 -
Effect of Erythropoiesis-Stimulating Agent Therapy in Patients Receiving Palliative Care of Chronic Kidney Disease
|
||
| Recruiting |
NCT03521713 -
To Evaluate the Efficacy, Safety, and Immunogenicity of Subcutaneous Eporon Versus Epoetin Alfa (Eprex)
|
Phase 3 | |
| Completed |
NCT02805244 -
Mass Balance Study of JTZ-951 in Subjects With End-stage Renal Disease on Hemodialysis
|
Phase 1 | |
| Completed |
NCT03428594 -
CKD-11101 Phase 3 IV Study in Patients Who Had Renal Anemia Receiving Hemodialysis
|
Phase 3 | |
| Recruiting |
NCT06463236 -
Clinical Validation of the Management Process for Renal Anemia in Maintenance Hemodialysis Patients
|
N/A | |
| Not yet recruiting |
NCT06352138 -
Comparative Study of Two Recombinant Human Erythropoietin Products on Chronic Kidney Disease Patients
|
Phase 3 |